Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIFED W/ CODEINE vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Codeine is a prodrug that is metabolized to morphine, which acts as a mu-opioid receptor agonist; triprolidine is an H1 receptor antagonist. The combination produces antitussive and antihistamine effects.
Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.
Symptomatic relief of cough and upper respiratory symptoms associated with allergy or cold
Moderate to severe pain where an opioid analgesic is appropriate
Adults: 10 m L orally every 4-6 hours as needed, not to exceed 4 doses in 24 hours. Each 10 m L contains 10 mg codeine, 4 mg triprolidine, 60 mg pseudoephedrine.
One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).
Codeine: 2.5-4 hours; pseudoephedrine: 5-8 hours; triprolidine: 3-6 hours. Context: Codeine half-life prolonged in hepatic impairment and CYP2D6 poor metabolizers; pseudoephedrine half-life increased with alkaline urine.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Pentazocine: 2-3 hours (terminal), with clinical analgesic effect lasting 3-4 hours.
Codeine is metabolized primarily via glucuronidation and O-demethylation to morphine by CYP2D6, and N-demethylation to norcodeine by CYP3A4. Triprolidine is metabolized by hepatic CYP450 enzymes.
Pentazocine is extensively metabolized in the liver via oxidation and glucuronidation; significant first-pass metabolism. Acetaminophen is metabolized primarily in the liver via conjugation with glucuronide and sulfate, and oxidation via CYP2E1, CYP1A2, and CYP3A4 to a toxic metabolite (NAPQI).
Renal: 60-80% (codeine and metabolites, primarily as codeine-6-glucuronide, norcodeine, and morphine); unchanged codeine <10%. Fecal: <10%. Biliary: minor.
Acetaminophen: renal (2-4% unchanged, ~85% as glucuronide and sulfate conjugates). Pentazocine: renal (~60% as unchanged and conjugates), biliary/fecal (~20%).
Codeine: 7-25% (primarily albumin); pseudoephedrine: negligible (<5%); triprolidine: approximately 85% (mainly albumin).
Acetaminophen: 10-25% (albumin). Pentazocine: 60-70% (albumin and alpha-1 acid glycoprotein).
Codeine: 3-6 L/kg; pseudoephedrine: 2.5-3.5 L/kg; triprolidine: 2-5 L/kg. Indicates extensive tissue distribution.
Acetaminophen: 0.9 L/kg. Pentazocine: 5-7 L/kg (extensive tissue distribution).
Codeine: 50-70% (oral); pseudoephedrine: 100% (oral); triprolidine: approximately 50% (oral) due to first-pass metabolism.
Acetaminophen oral: 60-90%. Pentazocine oral: ~20% (extensive first-pass metabolism). Intramuscular: pentazocine 100%.
GFR 30-59 m L/min: administer every 6 hours; GFR <30 m L/min: administer every 12 hours or avoid use due to risk of accumulation of codeine and pseudoephedrine; hemodialysis: not recommended.
Cr Cl 30-50 m L/min: use with caution; decrease dose interval to every 6 hours if needed. Cr Cl <30 m L/min: restrict pentazocine; consider alternative. Not recommended for patients on dialysis.
Child-Pugh A (mild): no adjustment; Child-Pugh B (moderate): reduce dose by 50% or extend interval to every 8 hours; Child-Pugh C (severe): avoid use due to risk of central nervous system depression.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce pentazocine dose by 50%; avoid acetaminophen >2 g/day. Child-Pugh Class C: contraindicated due to acetaminophen hepatotoxicity and pentazocine accumulation.
Not recommended in children <12 years due to risk of respiratory depression. For children ≥12 years: 10 m L orally every 4-6 hours as needed, max 4 doses in 24 hours. Weight-based dosing not established.
Not recommended in children <12 years due to lack of safety data. For adolescents ≥12 years, adult dosing may be considered based on weight (≥50 kg).
Start at lower dose (e.g., 5 m L orally every 6 hours) due to increased sensitivity to anticholinergic and sedative effects; monitor for confusion, urinary retention, and hypotension.
Reduce pentazocine dose by 50% (e.g., one tablet every 6 hours) due to increased risk of CNS depression, confusion, and constipation. Monitor renal function; avoid exceeding 4 g/day acetaminophen.
WARNING: RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYP2D6 GENETIC VARIABILITY; INTERACTION WITH ALCOHOL; RISKS FROM CONCOMITANT USE OF CYP3A4 INHIBITORS; RISKS IN PATIENTS WITH GASTROINTESTINAL CONDITIONS; RISKS OF USE IN PATIENTS WITH ASTHMA OR OTHER RESPIRATORY DISEASE; LABEL FOR INFANTS AND CHILDREN.
Pentazocine: Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Patients should be monitored for respiratory depression and sedation.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,CYP2D6 genetic variability (ultrarapid metabolizers),Accidental ingestion,Interaction with alcohol,Use in patients with gastrointestinal conditions,Use in patients with asthma or other respiratory disease,Avoid use in children <12 years
Respiratory depression risk, especially in patients with compromised respiratory function,Potential for opioid dependence, abuse, and misuse,Risk of withdrawal if discontinued abruptly after prolonged use,Pentazocine may cause opioid withdrawal in patients dependent on pure mu agonists,Acetaminophen hepatotoxicity at high doses or with chronic use; risk increased with alcohol consumption or pre-existing liver disease,Central nervous system depression additive with other CNS depressants,Elderly or debilitated patients may have increased sensitivity to effects,May cause hypotension, especially in hypovolemic patients,Serotonin syndrome risk when used with serotonergic drugs,Pentazocine may cause hallucinations, confusion, or other psychotomimetic effects
Hypersensitivity to codeine, triprolidine, or any component,Children <12 years,Postoperative management in children <18 years after tonsillectomy and/or adenoidectomy,Significant respiratory depression,Acute or severe bronchial asthma,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days,Paralytic ileus,Known CYP2D6 ultrarapid metabolizers
Hypersensitivity to either component,Severe respiratory depression (e.g., acute asthma, hypercapnia),Acute or severe bronchial asthma,Suspected surgical abdomen (may obscure diagnosis),Monoamine oxidase inhibitor (MAOI) use (current or within 14 days),Severe hepatic impairment or active liver disease (acetaminophen component),Known or suspected gastrointestinal obstruction (including paralytic ileus)
Avoid grapefruit and grapefruit juice as they may increase codeine levels and risk of adverse effects. High-tyramine foods (aged cheese, cured meats, fermented products) may interact with pseudoephedrine, potentially causing hypertensive crisis. Alcohol is contraindicated due to additive CNS depression.
Avoid alcohol consumption due to increased risk of hepatotoxicity from acetaminophen. No specific food interactions; take with food if gastrointestinal upset occurs.
First trimester: Codeine is associated with increased risk of congenital malformations (OR 1.24–2.0), particularly cardiac defects, with a dose-response relationship. Triprolidine and pseudoephedrine are generally considered low risk, but pseudoephedrine may be associated with gastroschisis (OR 1.8). Second trimester: Codeine may cause fetal dependence; pseudoephedrine may reduce uteroplacental blood flow. Third trimester: Codeine can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at delivery; pseudoephedrine may exacerbate pregnancy-induced hypertension. Overall, avoid in pregnancy for non-severe indications.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, use in third trimester may cause neonatal respiratory depression and withdrawal syndrome. Overall, risk is low but pentazocine should be avoided near term.
Codeine and pseudoephedrine are excreted into breast milk. M/P ratio for codeine is ~2.5; for pseudoephedrine, ~2.6–3.5. Use is contraindicated in breastfeeding due to risk of neonatal opioid toxicity (especially in CYP2D6 ultra-rapid metabolizers) and potential irritability/poor feeding from pseudoephedrine. Triprolidine has limited data but is considered compatible in low doses.
Acetaminophen: Excreted in low amounts (M/P ratio ~0.2-0.9); compatible with breastfeeding. Pentazocine: Excreted in breast milk; M/P ratio unknown; may cause CNS effects in infants. Use with caution, especially in neonates or premature infants. Monitor infant for sedation and respiratory depression.
No specific dose adjustments are established; however, due to increased renal clearance of pseudoephedrine in pregnancy, standard doses may be less effective. Codeine metabolism via CYP2D6 is variably affected by pregnancy (increased clearance ≈30–50% in second/third trimester), potentially requiring dose titration. Avoid use entirely in pregnancy; use alternative agents if needed.
Acetaminophen: No significant pharmacokinetic changes in pregnancy; standard dosing (max 3-4 g/day) applies. Pentazocine: Clearance may increase due to enhanced hepatic metabolism; dose adjustments not routinely recommended but monitor response. Avoid high doses near term due to risk of neonatal depression.
Actifed w/ Codeine combines triprolidine, pseudoephedrine, and codeine. Due to codeine's prodrug metabolism via CYP2D6, ultra-rapid metabolizers risk toxicity; contraindicated in children <12 years, post-tonsillectomy/adenoidectomy, and breastfeeding. Pseudoephedrine may cause hypertensive crisis with MAOIs. Triprolidine's anticholinergic effects exacerbate glaucoma, urinary retention, and cognitive impairment in elderly.
Pentazocine is a mixed agonist-antagonist opioid; avoid in opioid-dependent patients due to risk of precipitated withdrawal. Acetaminophen component limits total daily dose to 4 g (or less in hepatic impairment) to prevent hepatotoxicity. Monitor for respiratory depression, especially in elderly or those with COPD. Injection site reactions (e.g., sterile abscesses, fibrosis) common with repeated intramuscular use. May cause dysphoria, hallucinations, or CNS stimulation (unlike typical opioids). Contraindicated in acute porphyria due to porphyrinogenic potential.
Do not exceed recommended dose; risk of serious breathing problems, especially in children.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation and respiratory depression risk.,Store securely; codeine carries risk of dependence and misuse.,If pregnant or breastfeeding, consult prescriber; do not use while breastfeeding due to infant toxicity risk.,May cause drowsiness; avoid driving or operating heavy machinery until effects are known.,Inform healthcare provider of all medications, especially MAOIs (within 14 days), antidepressants, or blood pressure medications.,Discontinue and seek medical help if symptoms of allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing) occur.,Use caution with high blood pressure, thyroid problems, diabetes, or enlarged prostate.
Do not exceed 4 grams of acetaminophen per day from all sources (including OTC medications).,Avoid alcohol while taking this medication; risk of liver damage increases.,This medication may cause dizziness, drowsiness, or hallucinations; avoid driving or operating machinery until effects are known.,Report any signs of allergic reaction (rash, difficulty breathing) or liver issues (yellow skin/eyes, dark urine).,Do not suddenly stop if used long-term; withdrawal symptoms may occur.,If you have opioid dependence, this medication may precipitate withdrawal symptoms.,This medication may cause constipation; maintain fluid and fiber intake.
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
"Pentazocine, a mixed opioid agonist-antagonist, may attenuate the central nervous system (CNS) stimulant effects of dextroamphetamine by competitively blocking mu-opioid receptors and potentially altering dopamine release, leading to reduced analgesic efficacy of pentazocine and diminished therapeutic response to dextroamphetamine in treating attention deficit hyperactivity disorder (ADHD) or narcolepsy. This interaction can result in suboptimal pain control and exacerbation of ADHD symptoms, requiring dose adjustments or alternative therapies."
"The concurrent use of ipratropium, an anticholinergic agent, and pentazocine, a mixed opioid agonist-antagonist, may lead to an increased risk of central nervous system (CNS) depression and anticholinergic adverse effects. Pentazocine can enhance the sedative and respiratory depressant effects of ipratropium, while ipratropium may potentiate pentazocine's anticholinergic actions, such as dry mouth, blurred vision, constipation, and urinary retention. Clinically, this interaction can result in excessive sedation, confusion, and impaired cognitive and motor function, particularly in elderly or debilitated patients."
"The combination of pentazocine, a mixed agonist-antagonist opioid, with triazolam, a benzodiazepine, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and psychomotor impairment. This is due to the synergistic effects of both drugs on GABAergic and opioid receptors in the brainstem and cortex. Clinically, this may result in excessive drowsiness, confusion, ataxia, and an elevated risk of falls or respiratory compromise, particularly in elderly or debilitated patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIFED W/ CODEINE vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
ACTIFED W/ CODEINE is a Opioid Agonist that works by Codeine is a prodrug that is metabolized to morphine, which acts as a mu-opioid receptor agonist; triprolidine is an H1 receptor antagonist. The combination produces antitussive and antihistamine effects.. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIFED W/ CODEINE and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIFED W/ CODEINE is: Adults: 10 m L orally every 4-6 hours as needed, not to exceed 4 doses in 24 hours. Each 10 m L contains 10 mg codeine, 4 mg triprolidine, 60 mg pseudoephedrine.. The standard adult dose of ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is: One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIFED W/ CODEINE and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIFED W/ CODEINE is classified as Category D/X. First trimester: Codeine is associated with increased risk of congenital malformations (OR 1.24–2.0), particularly cardiac defects, with a dose-response relationship. Triprolidine . ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.